vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是Amphastar Pharmaceuticals, Inc.的1.4倍（$261.0M vs $183.1M），Liberty Broadband Corp净利率更高（146.7% vs 13.3%，领先133.4%），Liberty Broadband Corp同比增速更快（6.1% vs -1.8%），Liberty Broadband Corp自由现金流更多（$37.0M vs $24.6M），过去两年Liberty Broadband Corp的营收复合增速更高（4.3% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
AMPH vs LBRDA — 直观对比
营收规模更大
LBRDA
是对方的1.4倍
$183.1M
营收增速更快
LBRDA
高出7.9%
-1.8%
净利率更高
LBRDA
高出133.4%
13.3%
自由现金流更多
LBRDA
多$12.4M
$24.6M
两年增速更快
LBRDA
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $261.0M |
| 净利润 | $24.4M | $383.0M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 15.7% |
| 净利率 | 13.3% | 146.7% |
| 营收同比 | -1.8% | 6.1% |
| 净利润同比 | -35.7% | 96.4% |
| 每股收益（稀释后） | $0.51 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHLBRDA
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | — | ||
| Q2 25 | $174.4M | $261.0M | ||
| Q1 25 | $170.5M | $266.0M | ||
| Q4 24 | $186.5M | $263.0M | ||
| Q3 24 | $191.2M | $262.0M | ||
| Q2 24 | $182.4M | $246.0M | ||
| Q1 24 | $171.8M | $245.0M |
净利润AMPHLBRDA
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | — | ||
| Q2 25 | $31.0M | $383.0M | ||
| Q1 25 | $25.3M | $268.0M | ||
| Q4 24 | $38.0M | $291.0M | ||
| Q3 24 | $40.4M | $142.0M | ||
| Q2 24 | $37.9M | $195.0M | ||
| Q1 24 | $43.2M | $241.0M |
毛利率AMPHLBRDA
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHLBRDA
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | 15.7% | ||
| Q1 25 | 21.9% | 16.2% | ||
| Q4 24 | 24.2% | 4.9% | ||
| Q3 24 | 29.8% | 11.5% | ||
| Q2 24 | 30.3% | 8.5% | ||
| Q1 24 | 27.9% | 11.4% |
净利率AMPHLBRDA
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 17.8% | 146.7% | ||
| Q1 25 | 14.8% | 100.8% | ||
| Q4 24 | 20.4% | 110.6% | ||
| Q3 24 | 21.1% | 54.2% | ||
| Q2 24 | 20.8% | 79.3% | ||
| Q1 24 | 25.1% | 98.4% |
每股收益（稀释后）AMPHLBRDA
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | $2.68 | ||
| Q1 25 | $0.51 | $1.87 | ||
| Q4 24 | $0.74 | $2.04 | ||
| Q3 24 | $0.78 | $0.99 | ||
| Q2 24 | $0.73 | $1.36 | ||
| Q1 24 | $0.81 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $180.0M |
| 总债务越低越好 | $608.7M | $3.1B |
| 股东权益账面价值 | $788.8M | $10.4B |
| 总资产 | $1.6B | $16.6B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资AMPHLBRDA
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | $180.0M | ||
| Q1 25 | $236.9M | $226.0M | ||
| Q4 24 | $221.6M | $163.0M | ||
| Q3 24 | $250.5M | $168.0M | ||
| Q2 24 | $217.8M | $73.0M | ||
| Q1 24 | $289.6M | $108.0M |
总债务AMPHLBRDA
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | $3.1B | ||
| Q1 25 | $603.9M | $3.8B | ||
| Q4 24 | $601.6M | $3.8B | ||
| Q3 24 | $596.4M | $3.7B | ||
| Q2 24 | $586.9M | $3.6B | ||
| Q1 24 | $594.0M | $3.6B |
股东权益AMPHLBRDA
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | — | ||
| Q2 25 | $757.5M | $10.4B | ||
| Q1 25 | $751.3M | $10.1B | ||
| Q4 24 | $732.3M | $9.8B | ||
| Q3 24 | $727.7M | $9.5B | ||
| Q2 24 | $713.3M | $9.3B | ||
| Q1 24 | $672.4M | $9.1B |
总资产AMPHLBRDA
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.6B | $16.6B | ||
| Q1 25 | $1.6B | $17.0B | ||
| Q4 24 | $1.6B | $16.7B | ||
| Q3 24 | $1.5B | $16.3B | ||
| Q2 24 | $1.5B | $16.0B | ||
| Q1 24 | $1.6B | $15.7B |
负债/权益比AMPHLBRDA
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | 0.30× | ||
| Q1 25 | 0.80× | 0.38× | ||
| Q4 24 | 0.82× | 0.38× | ||
| Q3 24 | 0.82× | 0.39× | ||
| Q2 24 | 0.82× | 0.39× | ||
| Q1 24 | 0.88× | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $91.0M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $37.0M |
| 自由现金流率自由现金流/营收 | 13.4% | 14.2% |
| 资本支出强度资本支出/营收 | 4.5% | 20.7% |
| 现金转化率经营现金流/净利润 | 1.35× | 0.24× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-49.0M |
8季度趋势，按日历期对齐
经营现金流AMPHLBRDA
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | — | ||
| Q2 25 | $35.6M | $91.0M | ||
| Q1 25 | $35.1M | $78.0M | ||
| Q4 24 | $29.0M | $1.0M | ||
| Q3 24 | $60.0M | $24.0M | ||
| Q2 24 | $69.1M | $27.0M | ||
| Q1 24 | $55.3M | $52.0M |
自由现金流AMPHLBRDA
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | $37.0M | ||
| Q1 25 | $24.4M | $13.0M | ||
| Q4 24 | $16.6M | $-63.0M | ||
| Q3 24 | $46.2M | $-36.0M | ||
| Q2 24 | $63.1M | $-35.0M | ||
| Q1 24 | $46.5M | $-9.0M |
自由现金流率AMPHLBRDA
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | 14.2% | ||
| Q1 25 | 14.3% | 4.9% | ||
| Q4 24 | 8.9% | -24.0% | ||
| Q3 24 | 24.1% | -13.7% | ||
| Q2 24 | 34.6% | -14.2% | ||
| Q1 24 | 27.1% | -3.7% |
资本支出强度AMPHLBRDA
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | 20.7% | ||
| Q1 25 | 6.3% | 24.4% | ||
| Q4 24 | 6.7% | 24.3% | ||
| Q3 24 | 7.2% | 22.9% | ||
| Q2 24 | 3.3% | 25.2% | ||
| Q1 24 | 5.1% | 24.9% |
现金转化率AMPHLBRDA
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 0.24× | ||
| Q1 25 | 1.39× | 0.29× | ||
| Q4 24 | 0.76× | 0.00× | ||
| Q3 24 | 1.48× | 0.17× | ||
| Q2 24 | 1.82× | 0.14× | ||
| Q1 24 | 1.28× | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
LBRDA
暂无分部数据
